Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025

Supplemental Table 1 from Beyond the Promoter: Total MGMT Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNicole BricenoJJJinkyu JungALAmin Li

Discussion

Loading...

Member takes

Overview

Analyzing how MGMT gene methylation influences carmustine sensitivity and expression in glioma cells, indicating treatment implications.

Key Points

  • MGMT gene methylation significantly impacts sensitivity to carmustine, a key DNA-alkylating agent used in glioma therapy.
  • Combined evaluation of promoter and body methylation shows correlations with mRNA and protein expression levels.
  • Assessment conducted on glioma samples reveals the complex interplay between methylation patterns and drug response.
  • Understanding MGMT methylation can guide personalized treatment strategies in glioma management.

Cite This Study

Briceno et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a2196dhttps://doi.org/10.1158/1535-7163.30255697
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplemental Figure 1 from Beyond the Promoter: Total <i>MGMT</i> Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma2025
  2. 2Supplemental Figure 2 from Beyond the Promoter: Total <i>MGMT</i> Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma2025
  3. 3Data from Beyond the Promoter: Total <i>MGMT</i> Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma2025
  4. 4MGMT promoter methylation in malignant gliomas: ready for personalized medicine?2009 · 796 citations
  5. 5Correlation of O<sup>6</sup>-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity2008 · 808 citations